We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Research UK Team with MedImmune on Biotherapeutics Research Centre
News

Cancer Research UK Team with MedImmune on Biotherapeutics Research Centre

Cancer Research UK Team with MedImmune on Biotherapeutics Research Centre
News

Cancer Research UK Team with MedImmune on Biotherapeutics Research Centre

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Research UK Team with MedImmune on Biotherapeutics Research Centre "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The state-of-the-art CRUK-MEDI Alliance Laboratory, located on Granta Park, is an innovative collaboration between Cancer Research UK, its commercial arm Cancer Research Technology, and MedImmune, the global biologics research and development arm of AstraZeneca.

In this important partnership, both Cancer Research UK and MedImmune scientists will work together in the laboratory and collaborate closely to share knowledge and expertise to discover and develop novel biologics to treat and diagnose cancer. The alliance will bring together MedImmune’s world-class human antibody phage display libraries and protein-engineering expertise with Cancer Research UK’s cancer biology expertise.  

Cancer Research UK has provided the equipment and operational funding for the laboratory and will contribute a portfolio of novel drug targets through its extensive network of principal investigators. MedImmune will manage the drug discovery process for accepted projects. 

Dr Maria Groves, head of the CRUK-MEDI Alliance Laboratory and associate director at MedImmune, said: “This laboratory is truly a collaborative approach and its success will depend on three key factors: the application of our high-quality and diverse phage display libraries; designing a drug discovery process that will enable us to find specific potent antibodies with the right mechanism against the disease target and, finally, building a network of principal investigators who will have the opportunity to generate novel ideas for oncology therapeutics. We are driven to engineer the best antibodies and identify which components of cancer make the best targets for treatment. There’s a lot of ground to cover and we’re delighted to be working in partnership to advance this exciting field.”

Life Sciences Minister George Freeman said: “This pioneering new laboratory in Cambridge highlights the vital role that Cancer Research UK and other charities play in funding exciting medical research which has the potential to help many patients. This ambitious project unites academia and industry to translate world-leading research from the laboratory into crucial new treatments for patients. The UK is already leading the way in cancer research, and collaborations such as this help to ensure that we convert that science into new medicines.”

Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “Increasing investment in biotherapeutic treatment forms a key part of Cancer Research UK’s research strategy.

“We’re delighted to embark on this exciting new initiative, which will give leading Cancer Research UK scientists access to the latest antibody-engineering technologies and expertise. This will create opportunities to translate breakthroughs in our understanding of cancer biology into urgently needed new cancer treatments.”

Advertisement